^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    MI Cancer Seek™

    Company:
    Caris Life Sci
    Type:
    FDA Approved
    Related tests:

    Details

    Evidence
    News
    MI Cancer Seek™ is the first and only simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS)-based assay with FDA-approved CDx indications for molecular profiling of solid tumors. MI Cancer Seek is available for adult and pediatric (ages 1-22) patients.
    Cancer:
    Breast Cancer, Colorectal Cancer, Endometrial Cancer, Melanoma, Non Small Cell Lung Cancer, Solid Tumor
    Gene:
    BRAF (B-raf proto-oncogene), EGFR (Epidermal growth factor receptor), KRAS (KRAS proto-oncogene GTPase), MSI (Microsatellite instability), NRAS (Neuroblastoma RAS viral oncogene homolog), PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    Drug:
    Braftovi (encorafenib), Erbitux (cetuximab), Jemperli (dostarlimab-gxly), Keytruda (pembrolizumab), Lenvima (lenvatinib), Mekinist (trametinib), Piqray (alpelisib), Vectibix (panitumumab)
    Method:
    Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS)